Phase II Construction of NCNPR Research Wing

NCNPR研究楼二期建设

• 批准号: 7877557
• 负责人: LARRY A WALKER
• 金额: $ 1391.54万
• 依托单位: UNIVERSITY OF MISSISSIPPI
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2015-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7877557
• 关键词: Advanced Development; Area; Award; Basic Science; Biological Factors; Botanicals; Clinical Research; Commit; Development; Drug Delivery Systems; Drug Formulations; Floor; Fostering; Foundations; Funding; Health; Human; Laboratories; Mechanics; Mississippi; Molecular Mechanisms of Action; Pharmacologic Substance; Phase; Production; Request for Applications; Research; Research Project Grants; Safety; Technology; Therapeutic; Time; Toxic effect; Translations; Universities; Wing; analog; base; commercialization; design; dietary supplements; drug development; economic impact; falls; good laboratory practice; marine natural product; microbial; programs; scale up; symposium

DESCRIPTION (provided by applicant): The objective of this project is the completion of the construction of the University of Mississippi's National Center for Natural Products Research (NCNPR) Phase II research wing. This will entail addition of the top two floors, with completion of a portion of the first floor of this research wing, with a total of about 55,000 gross SF of new research space. Note that funds are already committed for the construction of the basement and substantial completion of the first floor; this is slated to begin in fall 2009, with an anticipated completion date in early 2011. This application requests funds to construct the second and third floors, and partial build-out for completion of the first floor, of the Phase II research wing as envisioned in the original NCNPR planning and in the Phase II facility programming document. This proposed project, if awarded, can be timed so as to be completed in concert with the currently funded component as a single, continuous construction. At the foundation of this NCNPR program are a number of PHS and other federally funded research projects aimed at discovery, design, and synthesis of new drugs and development of new drug delivery systems for unmet therapeutic needs in human health, an important national priority. Early development activities to facilitate commercialization of these technologies will also be a critical function for this program. Such efforts are key components for realization of the full potential economic impact of these natural product-based discoveries. In addition, the NCNPR has a strong and growing research effort to expand the scientific basis for enhancement of the authentication, quality and safety of botanical products used as dietary supplements in the US. Completion of this construction as planned will foster translation of basic research into clinical studies and commercial development as follows: 1) provide laboratories for scaling up extraction and isolation of bulk natural products in quantities that will support advanced development activities; 2) provide laboratories for scale-up synthesis and analog development; 3) provide Good Laboratory Practice-compliant analytical facilities that will support bioanalytical research, product and regulatory package development; 4) provide Good Manufacturing Practice-compliant facilities for production of active pharmaceutical ingredient (API); 5) provide laboratories for preformulation, formulation and stability studies to characterize APIs; 6) provide laboratories for cellular and molecular mechanism of action and toxicity studies; and 7) provide laboratories for expansion of discovery efforts with greater emphasis on microbial and marine natural products. The requested funding will support construction to include 55,127 gross SF (partial first floor, 7,117; second floor 24,005; third floor, 24,005). Four laboratories of about 860 SF will be included in the first floor section, with eight laboratories each on the second and third floors; laboratory and building/mechanical support areas and office/cubicle/conference spaces are also included on each floor. Total net laboratory, office and support spaces to be constructed with this requested funding on the three floors will be 23,011 SF of new laboratory space, 9,773 SF of new office space, and 15,460 SF in support areas.

描述（由申请人提供）：该项目的目标是完成密西西比大学国家天然产物研究中心（NCNPR）第二期研究翼的建设。这将需要增加顶部两层，并完成该研究侧楼一楼的一部分，新研究空间的总面积约为 55,000 平方英尺。请注意，资金已用于建造地下室和基本完成一楼；该项目计划于 2009 年秋季开始，预计完工日期为 2011 年初。本申请要求提供资金，按照最初的 NCNPR 规划和第二阶段设施规划文件中的设想，建造第二阶段研究翼的二楼和三楼，并部分扩建以完成一楼。该拟议项目如果获得批准，可以安排时间，以便与当前资助的部分作为一个单一的、连续的建设一起完成。该 NCNPR 计划的基础是许多 PHS 和其他联邦资助的研究项目，旨在发现、设计和合成新药以及开发新的药物输送系统，以满足人类健康中未满足的治疗需求，这是国家的重要优先事项。促进这些技术商业化的早期开发活动也将是该计划的关键职能。这些努力是实现这些基于天然产物的发现的全部潜在经济影响的关键组成部分。此外，NCNPR 还开展了强大且不断增长的研究工作，以扩大科学基础，以增强美国用作膳食补充剂的植物产品的认证、质量和安全性。按计划完成该建设将促进基础研究向临床研究和商业开发的转化，具体如下：1）提供实验室，扩大批量天然产物的提取和分离规模，以支持先进的开发活动； 2) 提供放大合成和模拟开发的实验室； 3) 提供符合良好实验室规范的分析设施，以支持生物分析研究、产品和监管包开发； 4) 提供符合良好生产规范的设施来生产活性药物成分（API）； 5) 提供用于预制剂、制剂和稳定性研究的实验室来表征原料药； 6) 提供细胞和分子作用机制及毒性研究的实验室； 7) 提供实验室以扩大发现工作，更加重视微生物和海洋天然产物。所申请的资金将用于支持建筑面积 55,127 平方英尺（一楼部分 7,117 间；二楼 24,005 间；三楼 24,005 间）。一楼部分将包括四个约860平方英尺的实验室，二楼和三楼各有八个实验室；每层还包括实验室和建筑/机械支持区域以及办公室/隔间/会议空间。利用这笔资金在三层楼建造的净实验室、办公室和支持空间总计为 23,011 平方英尺的新实验室空间、9,773 平方英尺的新办公空间和 15,460 平方英尺的支持区域。